OCUGEN, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
OCUGEN, INC. (OCGN) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $36.00 thousand as of 2015-12-31, per its 10-K filed 2017-03-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2017-03-16
- 2015-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $36.00K.
- 2014-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $121.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2015-12-31 | $36.00K 10-K · filed 2017-03-16 |
| 2014-12-31 | $121.00K 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |